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What you need to know:
The safety of pharmaceutical drugs in Canada 
is a concern. While Health Canada is given the 
power to measure safety and approve drugs, 
the process has its limits. There is a growing 
trend towards practicing “risk management” 
rather than the “precautionary principle” when 
drugs are approved. There is also a greater 
priority put on meeting the interest of drug 
companies compared to the potential harm to 
public health. “Progressive licensing” would 
allow for drugs to be assessed for safety even 
after it’s approved.  
What is this research about?
Prescription drugs go through a process of 
monitoring and approval in order to measure 
their benefits and risks. The Food and Drugs Act 
names Health Canada as responsible for this.  
However, drug companies are almost invariably 
a part of the negotiations for removing unsafe 
drugs from the shelves. As a result, Health 
Canada’s power is limited. They can issue a 
public warning about a drug, but they do not 
have the power to recall the drug without the 
company’s agreement. There is also a growing 
concern that decisions to approve drug products 
as “safe” are based on market friendly choices 
rather than concern for public health. The faster 
the drug approval process becomes, the less 
time there is to assess potential risks of these 
new products.  
What did the researcher do?
The researcher began by examining some of the 
limits of Health Canada’s legal power. He also 
examined the growing trend towards a business-
friendly process in assessing drug safety, both in 
policy and with funding. The researcher looked at
both the positive and negative attributes of how 
Health Canada manages information regarding 
drug safety in Canada. Finally, he evaluated one 
possible alternative for improving the ability to 
assess drug safety.   
What did the researcher find?
The researcher found that the authority and 
actions of Health Canada were geared towards 
making it easier for drugs to become approved. 
This was at the expense of a more a thorough 
process to assess their safety. Health Canada 
does not have the authority to recall a product 
if it is considered harmful. They may issue a 
public warning, but it is up to the manufacturer 
to withdraw it from store shelves. Companies 
cannot be forced to conduct new studies 
regarding the safety of a product once it has 
been approved for the market. The Marketed 
Health Products Directorate (MPHD), a division 
of Health Canada, monitors the safety of 
drugs after they are approved, but they have 
limited resources. As a result, they have had to 
stop routinely assessing how likely it is that a 
drug caused an ADR (adverse drug reaction) 
when an adverse reaction report is received. 
Meanwhile, the Therapeutic Products Directorate 
(TPD), another division of Health Canada, is 
responsible for approving drugs, and receives 
one third of its funding from drug companies. The 
TPD is moving towards faster drug approvals 
and practicing “risk management” over the 
“precautionary principle”.
The researcher also found some problems with 
different aspects of how Health Canada oversees 
drug safety. Health Canada has no standards for 
how long it should take between when an ADR 
report is filed and when it becomes posted on 
their website. There was also poor information 
on how Health Canada decides whether a 
safety issue should be communicated to health 
care professionals and the public. Compared to 
other countries, Canada allows its ADR reports 
to be accessed by the public on the internet. 
However, ADR databases are known to only 
cover 1 to 10 percent of all reactions to a drug 
because of under-reporting of ADRs by health 
care professionals. Information from clinical trials 
done before a drug is approved that assess 
how well the drug works and how safe it is, is 
also confidential, unless the company agrees 
to have it released. The researcher argued that 
“progressive licensing” was a useful alternative 
for Health Canada. Progressive licensing moves 
away from the “all or nothing” dynamic in drug 
approvals and allows safety to be assessed 
throughout the entire time a drug is on the 
market.
How can you use this research?
This research would be useful for service 
providers in the health industry. They might use 
it to improve public education on the risks and 
benefits of drugs on the market. This research 
would also be useful for policy makers dealing 
with public health and business interests. It 
offers insight on how to regulate the relationship 
between the two parties.    
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